Total Payments
$1.0M
2024 Payments
$1,062
Companies
9
Transactions
117
Medicare Patients
644
Medicare Billing
$36,397
Payment Breakdown by Category
Research$1.0M (98.0%)
Consulting$15,740 (1.5%)
Travel$4,470 (0.4%)
Food & Beverage$719.92 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.0M | 73 | 98.0% |
| Consulting Fee | $15,740 | 3 | 1.5% |
| Travel and Lodging | $4,470 | 7 | 0.4% |
| Food and Beverage | $719.92 | 34 | 0.1% |
Payments by Type
Research
$1.0M
73 transactions
General
$20,930
44 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $962,608 | 71 | $0 (2022) |
| Bausch Health US, LLC | $30,275 | 13 | $0 (2019) |
| Merz North America, Inc. | $14,064 | 4 | $0 (2018) |
| ABBVIE INC. | $13,122 | 15 | $0 (2024) |
| Endo Pharmaceuticals Inc. | $1,962 | 8 | $0 (2018) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $27.62 | 2 | $0 (2024) |
| Medtronic, Inc. | $25.91 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $25.40 | 2 | $0 (2017) |
| Lilly USA, LLC | $18.84 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,062 | 10 | ABBVIE INC. ($1,021) |
| 2023 | $12,102 | 7 | AbbVie Inc. ($12,102) |
| 2022 | $26,175 | 9 | Allergan, Inc. ($26,163) |
| 2021 | $15.56 | 1 | Allergan, Inc. ($15.56) |
| 2020 | $546,501 | 34 | Allergan, Inc. ($546,501) |
| 2019 | $411,466 | 22 | Allergan Inc. ($385,110) |
| 2018 | $20,443 | 23 | Merz North America, Inc. ($14,048) |
| 2017 | $4,364 | 11 | Allergan Inc. ($4,304) |
All Payment Transactions
117 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $12.68 | General |
| 09/05/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $10.42 | General |
| 08/28/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | JUBLIA (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Podiatry | ||||||
| 05/22/2024 | Medtronic, Inc. | VENASEAL (Device) | Food and Beverage | In-kind items and services | $25.91 | General |
| Category: EndoVenous Therapies | ||||||
| 05/15/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $6.21 | General |
| Category: IMMUNOLOGY | ||||||
| 05/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: FACIAL AESTHETICS | ||||||
| 02/24/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $444.96 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 02/24/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $76.42 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 02/23/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $326.43 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 02/23/2024 | ABBVIE INC. | BOTOX (Biological) | — | In-kind items and services | $130.00 | Research |
| Study: BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study • Category: FACIAL AESTHETICS | ||||||
| 10/03/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $10.82 | General |
| Category: FACIAL AESTHETICS | ||||||
| 10/03/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $4.50 | General |
| Category: FACIAL AESTHETICS | ||||||
| 09/21/2023 | AbbVie Inc. | NATRELLE SALINE-FILLED BREAST IMPLANTS (Device) | Food and Beverage | In-kind items and services | $8.84 | General |
| Category: PLASTIC SURGERY | ||||||
| 08/25/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $1,725.00 | General |
| 08/09/2023 | AbbVie Inc. | BOTOX (Biological) | — | Cash or cash equivalent | $10,320.00 | Research |
| Study: Multicenter, Double-Blind, Randomized, Placebo-controlled, Dose-Ranging Phase 2 Active Comparator Study Evaluating the Efficacy and Safety of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines • Category: FACIAL AESTHETICS | ||||||
| 03/28/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: FACIAL AESTHETICS | ||||||
| 03/28/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $11.46 | General |
| Category: FACIAL AESTHETICS | ||||||
| 12/20/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $4.26 | General |
| Category: FACIAL AESTHETICS | ||||||
| 11/16/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: FACIAL AESTHETICS | ||||||
| 10/12/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $8.92 | General |
| Category: FACIAL AESTHETICS | ||||||
| 08/30/2022 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $3.22 | General |
| 08/22/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $7.01 | General |
| Category: FACIAL AESTHETICS | ||||||
| 06/02/2022 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $16.22 | General |
| 05/18/2022 | Ortho Dermatologics, a division of Bausch Health US, LLC | JUBLIA (Drug) | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: Podiatry | ||||||
| 05/10/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: FACIAL AESTHETICS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Ph 3 Pivotal GL and GL+LCL - US/EU | Allergan, Inc. | $252,522 | 13 |
| Ph 3 Pivotal GL and GLLCL - USEU | Allergan Inc. | $239,530 | 6 |
| Ph 3 Pivotal LCL Only - US/EU | Allergan, Inc. | $181,873 | 13 |
| Ph 3 Pivotal LCL Only - USEU | Allergan Inc. | $141,579 | 7 |
| Ph 3 Open-label Extension Study | Allergan, Inc. | $138,159 | 7 |
| MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2-ARM, PARALLEL GROUP EFFICACYSAFETY STUDY | Bausch Health US, LLC | $25,434 | 7 |
| Multicenter, Double-Blind, Randomized, Placebo-controlled, Dose-Ranging Phase 2 Active Comparator Study Evaluating the Efficacy and Safety of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines | AbbVie Inc. | $10,320 | 1 |
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $4,023 | 4 |
| Ph 3 Open-label Extension Study | Allergan Inc. | $4,000 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy Cellulite | Endo Pharmaceuticals Inc. | $1,962 | 8 |
| BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | ABBVIE INC. | $977.81 | 4 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris | Bausch Health US, LLC | $818.65 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 161 | 294 | $15,962 | $9,045 |
| 2022 | 6 | 159 | 254 | $15,313 | $9,034 |
| 2021 | 6 | 157 | 238 | $16,270 | $8,741 |
| 2020 | 6 | 167 | 262 | $16,176 | $9,576 |
Total Patients
644
Total Services
1,048
Medicare Billing
$36,397
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 28 | 43 | $4,894 | $2,849 | 58.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 42 | 67 | $3,980 | $2,346 | 59.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 24 | 25 | $3,275 | $1,918 | 58.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 17 | 20 | $1,895 | $861.51 | 45.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 15 | 17 | $1,015 | $582.97 | 57.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 35 | 122 | $903.00 | $487.28 | 54.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 27 | 35 | $4,017 | $2,458 | 61.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 40 | 55 | $3,592 | $2,041 | 56.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 18 | 21 | $2,876 | $1,974 | 68.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 29 | 37 | $2,390 | $1,306 | 54.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 18 | $1,711 | $888.63 | 51.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 29 | 88 | $727.00 | $366.43 | 50.4% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 35 | 52 | $5,825 | $3,035 | 52.1% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 29 | 31 | $4,245 | $2,287 | 53.9% |
| 17000 | Destruction of skin growth | Office | 2021 | 33 | 43 | $2,568 | $1,486 | 57.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 24 | $2,143 | $1,232 | 57.5% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 14 | 15 | $959.00 | $461.40 | 48.1% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 23 | 73 | $530.00 | $240.09 | 45.3% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 38 | 51 | $5,740 | $3,425 | 59.7% |
| 11104 | Punch biopsy of single skin lesion | Office | 2020 | 20 | 22 | $2,992 | $1,680 | 56.2% |
| 17000 | Destruction of skin growth | Office | 2020 | 33 | 47 | $2,994 | $1,641 | 54.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 26 | 32 | $2,480 | $1,558 | 62.8% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 23 | 30 | $1,485 | $960.09 | 64.7% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 27 | 80 | $485.00 | $311.44 | 64.2% |
About Dr. William Coleman, M.D
Dr. William Coleman, M.D is a Procedural Dermatology healthcare provider based in Metairie, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861585283.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Coleman, M.D has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $1,062 received in 2024. These payments were reported across 117 transactions from 9 companies. The most common payment nature is "" ($1.0M).
As a Medicare-enrolled provider, Coleman has provided services to 644 Medicare beneficiaries, totaling 1,048 services with total Medicare billing of $36,397. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Procedural Dermatology
- Location Metairie, LA
- Active Since 09/30/2006
- Last Updated 10/18/2007
- Taxonomy Code 207NS0135X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1861585283
Products in Payments
- BOTOX (Biological) $15,719
- XEOMIN (Biological) $14,048
- BOTOX COSMETIC (Biological) $39.18
- JUBLIA (Drug) $27.62
- VENASEAL (Device) $25.91
- STELARA (Biological) $25.40
- TALTZ (Drug) $18.84
- Xeomin (Biological) $15.95
- ACZONE (Drug) $11.00
- NATRELLE SALINE-FILLED BREAST IMPLANTS (Device) $8.84
- SKYRIZI (Biological) $6.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.